0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Selective Control by Corticosterone of Serotonin Receptor Capacity in Raphe-Hippocampal System

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The effect of short-term bilateral adrenalectomy (ADX) and corticosterone or aldosterone replacement was investigated on serotonin<sub>1</sub> (5-HT<sub>1</sub>) receptor density in rat brain regions. One hour after ADX the 5-HT<sub>1</sub> receptor density was increased in subiculum, molecular layer of the dentate gyrus, substantia nigra, and dorsal raphe nucleus as shown by in vitro autoradiography and computerized densitometric analyses of the film images. In subiculum, dentate gyrus, and dorsal raphe nucleus the 5-HT<sub>1</sub> receptor density was restored (decreased) towards the level observed in sham-operated rats after administration of a low dose of corticosterone (CORT) at the time of ADX. CORT replacement decreased the 5-HT<sub>1</sub> receptor number also in hippocampal pyramidal cell layer CA<sub>1</sub>, presubiculum, and other dentate gyrus subregions. The 5-HT<sub>1</sub> receptor density was not affected by ADX or CORT replacement therapy in cerebral cortex, central grey, CA<sub>3</sub>, ventral hippocampus, and median raphe nucleus. Aldosterone administered under the same experimental conditions did not change the 5-HT<sub>1</sub> receptor number in any of the hippocampus or raphe regions. The dose of CORT (30 µg/100 g body weight, s.c.) gave physiological plasma levels and maintained almost complete occupation of CORT receptors (mineralo-corticoid-like receptors) in hippocampus which was also the case in the sham-operated control animals. CORT replacement did not maintain occupancy of glucocorticoid receptors in hippocampus. When the binding of the selective glucocorticoid agonist, Η-RU 28362, was taken as 100% at 1 h after ADX, CORT replacement and sham ADX left 75 and 50% of these sites available respectively. It is concluded that the 5-HT<sub>1</sub> receptor density in dorsal raphe and dorsal hippocampus regions is under selective control of CORT and that this 5-HT response seems to require occupation of the CORT(mineral-ocorticoid-like) receptor system in hippocampus neurons.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1986
          1986
          01 April 2008
          : 42
          : 6
          : 513-521
          Affiliations
          Rudolf Magnus Institute for Pharmacology, Medical Faculty, University of Utrecht, The Netherlands
          Article
          124496 Neuroendocrinology 1986;42:513–521
          10.1159/000124496
          3010158
          © 1986 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 9
          Categories
          Original Paper

          Comments

          Comment on this article